苯甲酸阿格列汀致肝损伤

Liver injury due to alogliptin benzoate

1例57岁男性2型糖尿病患者口服苯甲酸阿格列汀25 mg、1次/d,用药前肝功能正常。服用阿格列汀25 d后,患者出现皮肤黄染、乏力。实验室检查示总胆红素(TBil)65 μmol/L,丙氨酸转氨酶(ALT)2 856 U/L,天冬氨酸转氨酶(AST)1 028 U/L,碱性磷酸酶(ALP)124 U/L。排除病毒性肝炎、自身免疫性肝病和梗阻性黄疸后,考虑为苯甲酸阿格列汀导致的肝损伤。停用该药并给予保肝治疗。17 d后,患者上述症状消失,实验室检查示TBil 17 μmol/L,ALT 112 U/L,AST 30 U/L,ALP 76 U/L。

A 57‑year‑old male patient with type 2 diabetes mellitus was treated with alogliptin benzoate 25 mg once daily orally.His liver function was normal before the treatment.The patient developed yellowish skin and fatigue after 25 days of treatment.Laboratory tests showed total bilirubin(TBil)65μmol/L,alanine aminotransferase(ALT)2856 U/L,aspartate aminotransferase(AST)1028 U/L,and alkaline phos‑phatase(ALP)124 U/L.After excluding viral hepatitis,autoimmune liver disease,and obstructive jaundice,liver injury caused by alogliptin benzoate was considered.The drug was stopped and liver protective treat‑ments were given.Seventeen days later,the patient′s symptoms disappeared,and laboratory tests showed TBil 17μmol/L,ALT 112 U/L,AST 30 U/L,and ALP 76 U/L.